AnaptysBio, Inc (ANAB) stock

ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 9/30

$49.24+2.63 (+5.64%)

Close on Oct 19, 2026Market cap $1.73BP/E –Yield –

AnaptysBio statistics

37 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: –
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: –

Share statisticsIndustry

Shares Outstanding: 30M; 58M
Shares Change (YoY): 16.3%; 10.8%
Shares Change (QoQ): 0.72%; 0.50%
Float: 21M; 49M
Shares Held by Insiders: 28.7%; 11.7%
Shares Held by Institutions: 100.8%; 56.4%

MarginsIndustry

Operating Margin: 155.6%; -38.7%
Pretax Margin: 116.5%; -11.6%
Profit Margin: 96.3%; -31.6%
EBITDA Margin: 155.4%; -27.7%

Returns on capitalIndustry

Return on Assets (ROA): 55.9%; -40.6%
Return on Capital Employed (ROCE): 104.7%; -37.9%

Financial positionIndustry

Current Ratio: 8.40; 3.30
Quick Ratio: 8.18; 2.39

GrowthIndustry

Revenue Growth (YoY): 13.0%; 6.82%
Revenue Growth (3Y CAGR): 183.6%; 2.25%
Revenue Growth (5Y CAGR): 25.6%; 6.41%

EfficiencyIndustry

Asset Turnover: 0.58; 0.40
Revenue Per Employee: $1.84M; $429.29K
Profits Per Employee: $1.77M; -$689.41K
Employee Count: 104; 74

Income statement (TTM)Industry

Revenue: $191.57M; $66.37M
Operating Income: $298.13M; -$21.37M
Pretax Income: $223.21M; -$12.95M
Net Income: $184.49M; -$22.35M
EBITDA: $297.74M; -$17.21M

Balance sheetIndustry

Cash & Short-Term Investments: $152.99M; $68.68M
Net Cash (Debt): $152.99M; $17.76M
Net Cash Per Share: $5.12; $0.80
Equity (Book Value): $20.82M; $53.89M
Book Value Per Share: $0.70; $1.50
Tangible Book Value: $20.82M; $27.13M
Working Capital: $165.95M; $79.99M

Cash flow (TTM)Industry

Operating Cash Flow: $35.89M; -$12.38M

Taxes and interestIndustry

Income Tax: -$181.37M; $73.00K
Effective Tax Rate: -81.3%; 20.9%

Scores and fair valueIndustry

Piotroski F-Score: 5; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

Period	ANAB	S&P 500	Difference	ANAB per year	S&P 500 per year
1 month	-10.8%	+0.6%	−11.4 pts
3 months	-15.1%	+3.4%	−18.5 pts
Year to date	+52.4%	+13.3%	+39.1 pts
1 year	+113.3%	+16.6%	+96.7 pts
3 years	+314.5%	+86.4%	+228.1 pts	+60.6%	+23.1%
5 years	+169.2%	+81.9%	+87.3 pts	+21.9%	+12.7%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

5M ANAB shares were sold short on Oct 30, 2026, down 6.3% from the previous report. At recent volumes it would take 10.8 days to buy them back. Over the last 20 sessions, 47.0% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	5,050,250	-6.3%	468,120	10.8
Oct 15, 2026	5,392,123	+3.0%	507,972	10.6
Sep 30, 2026	5,236,151	-3.7%	639,524	8.2
Sep 15, 2026	5,437,438	+0.5%	530,306	10.3
Aug 31, 2026	5,412,436	+1.8%	347,135	15.6
Aug 14, 2026	5,317,981	-1.6%	372,089	14.3
Jul 31, 2026	5,401,866	+8.0%	749,400	7.2
Jul 15, 2026	4,999,494	-2.9%	853,496	5.9
Jun 30, 2026	5,148,302	+11.2%	622,514	8.3
Jun 15, 2026	4,631,786	-3.9%	566,928	8.2
May 29, 2026	4,821,283	+0.5%	489,677	9.8
May 15, 2026	4,796,235	+7.5%	660,958	7.3